Alexion Pharmaceuticals Director, Global Scientific Communications, PNH in Boston, Massachusetts
The Director, Scientific Communications, Hematology leads the successful development and implementation of global communications strategies, publications plans and medical education initiatives across Hematology therapeutic areas in alignment with Alexion brand and corporate strategies. The Director will chair the Hematology TA Global Publication Team as well as engage with cross-functional partners including but not limited to research, clinical development, marketing, medical affairs and biostats. In this role, the Director will develop collaborative and productive relationships with external investigators, thought leaders and authors. These efforts will ultimately drive timely execution of publication plans and result in high-quality and impactful scientific and clinical abstracts, posters, oral presentations, manuscripts, and slide decks. Analysis and interpretation of scientific and clinical data as well as review of deliverables from cross-functional publications team members and agencies for content and key messages are central responsibilities of this role. The Director will also be responsible for the identification and supervision of medical communications agencies and may also work/oversee medical writing consultants. This position reports to the Senior Director, Global Medical Communications for Hematology & Nephrology
Lead the creation of global communications strategies and publication plans for therapeutic areas within the Hematology franchise in accordance with the existing global brand strategies
Serve as Chair of the Global Publication Team(s) for assigned products and indication
Lead the timely execution of publication plans to produce high quality, accurate and impactful deliverables including abstracts, posters, oral presentations, manuscripts, and slide decks
Plan, develop and implement educational plan, and other scientific programs that communicate important information to the medical and scientific community.
Establish strong collaborative relationships and work in close partnership with other members of Global Medical Communications (Medical Information/Medical Review, Training, and Med Comms Excellence, Global Medical Affairs (HEOR, MSLs) and key stakeholders internally (product teams, clinical teams, biostats) and externally (e.g., opinion leaders, patient advocacy groups, professional societies).
Review publications, slide presentations and other scientific materials for content and positioning
Develop/update key strategic documents (Scientific Platforms), with consistent coverage of the competitive landscape.
Develop and evolve tactical publication plans based on therapeutic area medical objectives.
Identify, screen, manage and supervise medical communications agencies and manage financial and contractual aspects of assigned projects
Participate in training on as well as ensure compliance with the Alexion Publication Policy and associated processes
Advanced degree: PhD, PharmD, or MD
7-10 years of relevant experience in a Pharmaceutical company or Medical Communications agency, or at least 15 years of independent Scientific Communications / Publications consultancies for the Pharmaceutical Industry
Strong experience in strategic publication planning (including scientific platforms), tactical publication planning and implementation, and the planning and development of medical educational materials
Ability to work independently to develop strategic and tactical publication plans
Ability to rapidly develop expertise and critical knowledge in new therapeutic areas to support pipeline, investigational, and marketed projects from a strategic and tactical perspective
Ability to interpret and organize highly complex scientific data, including experience reviewing pre-clinical and clinical trial data and output from statistical analysis programs
Must be skilled, detail-oriented writer with demonstrated ability to critically interpret and contextualize clinical data for translation to physicians, patients and payers
Strong success in achieving acceptance of abstracts/manuscripts into the peer-reviewed literature
Strong working knowledge of current good publication practices, guidelines, and ethics.
Demonstrated experience in having a leadership role in designing scientific communications strategy and programs in alignment with corporate strategies
Understanding of the clinical development process, especially clinical study and global health outcome data.
Ability to lead teams, including medical publications agencies to plan, write and develop abstracts, posters, oral presentations, manuscripts, slide decks and content for scientific and educational programs
Experience in working closely with KOLs and authors
Demonstrated leadership skills
Ability to travel (US and International) as necessary
PhD in Life Science, CMPP certified
Experience in planning and implementation of formal peer-to-peer engagements (advisory boards, workshops for the planning and development of scientific publications or medical education materials)
Background in hematology
Some opportunities happen only once in a lifetime - like a job where you have the extraordinary opportunity to change lives. At Alexion, such opportunities arise through our unwavering mission to serve patients and families affected by rare diseases. These patients are our guiding star, and we act with integrity, urgency, and discipline because we know their lives are at stake.
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, metabolic disorders and cardiology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. Further information about Alexion can be found at: www.alexion.com.
As a leading employer in our industry, Alexion is proud to offer a highly competitive package of base and incentive compensation as well as a comprehensive benefits program designed to support the health, wellness and financial security of our employees and their families. Benefits include group medical, vision and dental coverage, group and supplemental life insurance, 401(k) with company match, tuition reimbursement, relocation assistance and much more.